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Abstract
Inactive DNA methyltransferase (DNMT) 3B splice isoforms are associated with changes in DNA methylation, yet the
mechanisms by which they act remain largely unknown. Using biochemical and cell culture assays, we show here that the
inactive DNMT3B3 and DNMT3B4 isoforms bind to and regulate the activity of catalytically competent DNMT3A or DNMT3B
molecules. DNMT3B3 modestly stimulated the de novo methylation activity of DNMT3A and also counteracted the
stimulatory effects of DNMT3L, therefore leading to subtle and contrasting effects on activity. DNMT3B4, by contrast,
significantly inhibited de novo DNA methylation by active DNMT3 molecules, most likely due to its ability to reduce the DNA
binding affinity of co-complexes, thereby sequestering them away from their substrate. Immunocytochemistry experiments
revealed that in addition to their effects on the intrinsic catalytic function of active DNMT3 enzymes, DNMT3B3 and
DNMT34 drive distinct types of chromatin compaction and patterns of histone 3 lysine 9 tri-methylation (H3K9me3)
deposition. Our findings suggest that regulation of active DNMT3 members through the formation of co-complexes with
inactive DNMT3 variants is a general mechanism by which DNMT3 variants function. This may account for some of the
changes in DNA methylation patterns observed during development and disease.
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Introduction
Mammalian cytosine methylation is a key epigenetic modifica-
tion that is maintained upon cell division and thus represents a
form of cellular memory. It is involved in regulation of gene
expression, silencing of parasitic transposable elements, X-
chromosome inactivation, genomic imprinting, the maintenance
of genomic stability, and is consistently altered in human cancers
[1,2,3]. Three DNA methyltransferases (DNMTs) actively catalyze
the transfer of methyl groups to CpG sites in mammals, including
DNMT1, DNMT3A, and DNMT3B [2]. DNMT3A and
DNMT3B primarily act as de novo enzymes, setting up the initial
patterns of DNA methylation during early embryonic develop-
ment, while DNMT1 primarily acts as a maintenance DNMT,
copying DNA methylation patterns upon cell division [4,5]. In
addition to these three active enzymes, a catalytically inactive
DNMT3 variant, the DNMT3-Like protein, DNMT3L, plays an
essential role in de novo DNA methylation [6]. DNMT3L operates
by binding to and reorganizing large heterogeneous DNMT3A or
DNMT3B complexes into defined heterodimeric DNMT3A or
DNMT3B:DNMT3L sub-complexes with higher affinity for S-
Adenosyl-L-Methionine (SAM), increased catalytic output, and
higher processivity [7,8,9,10,11,12,13].
Interestingly, over thirty different isoforms of DNMT3B,
resulting from alternative splicing and/or alternative promoter
usage, have been reported [14,15,16,17]. Splicing patterns and
spatio-temporal patterns of isoform expression appear to be
conserved between humans and mice, suggesting that these
isoforms carry biological significance [18]. Despite this conserva-
tion, their functions in normal and disease states remain largely
unclear. Several of these DNMT3B variants are missing key
regions of their C-terminal catalytic domain, rendering them
catalytically inactive. Some of these variants were reported to be
overexpressed in various cancers and to be associated with global
changes in DNA methylation [14,15,16,17,18,19,20,21]. For
instance, overexpression of DNMT3B7, a major splice variant
found in numerous tumor types, triggers both global and local
changes in DNA methylation patterns as well as chromosomal
rearrangements [16,22]. Likewise, DNMT3B3D5 is upregulated in
liver and skin cancer cell lines and its overexpression in HCT116
cells results in loss of DNA methylation at centromeric and
pericentromeric repetitive elements [17]. Though the expression
of inactive DNMT3B variants is associated with changes in DNA
methylation, little is known about the mechanisms that underlie
these changes at the molecular level.
In the present study, we sought to better understand how
inactive DNMT3B variants are involved in DNA methylation,
focusing on two inactive DNMT3B variants. The DNMT3B3
isoform, which lacks all sequences located between catalytic motifs
VIII and IX, including the first nine amino acids of catalytic motif
IX (Figure S1A), is ubiquitously expressed in normal human
tissues [23]. Intriguingly, the expression pattern of DNMT3B is
shifted from DNMT3B1 to DNMT3B3 immediately upon
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differentiation of human embryonic stem (ES) cells [24]. Expres-
sion analyses show that DNMT3B3 is overexpressed in numerous
cancerous tissues and tumor cell lines [25], and its expression was
reported to be essential for cancer cell survival [26]. DNMT3B3
has been shown to either contribute to DNA methylation activity
or to be associated with the ability to maintain aberrant DNA
methylation patterns in cancer [25,26,27]. The possible involve-
ment of DNMT3B3 in the deposition and/or maintenance of
DNA methylation patterns is intriguing given that it is catalytically
inactive [19,21,28]. The DNMT3B4 isoform corresponds to a
truncated DNMT3B variant lacking exons 21–23 encompassing
all residues located downstream of conserved motif XIII [14]
(Figure S1A). DNMT3B4 is expressed in multiple tissues in mouse
[23], but appears to be overexpressed in hepatocellular carcinomas
(HCCs), for which DNMT3B4 overexpression is significantly
correlated with DNA hypomethylation at pericentric satellite
repeats [20]. In chronic myeloid leukemia, increased levels of
DNMT3B4 are associated with LINE1 DNA hypomethylation
[29]. In addition, HEK293 cell lines that stably overexpress
DNMT3B4 display demethylation of satellite 2 after multiple
rounds of passages [20]. This suggests that overexpression of
DNMT3B4 somehow induces loss of DNA methylation.
Here, we used DNMT3L as a paradigm for the regulation of de
novo DNMTs by inactive variants and tested the hypothesis that
inactive DNMT3B isoforms can form complexes with, and
modulate the activity of, catalytically competent DNMT3B or
DNMT3A isoforms. Our data shows that DNMT3B3 binds to
catalytically competent DNMT3 molecules and modulates their
catalytic activity. DNMT3B4 also binds to catalytically competent
DNMT3 molecules; however complex formation leads to a strong
reduction in DNA binding and DNMT activity, causing a
dominant-negative inhibition. Our results suggest that binding
and regulation of active DNMT3 variants by inactive DNMT3B
variants is a general mechanism accounting, at least in part, for
some of the changes in DNA methylation profiles observed in
normal and disease states.
Materials and Methods
Expression Vectors
Mammalian expression vectors carrying N-terminally Myc- and
FLAG- tagged human DNMT3B1, DNMT3B2, DNMT3B3,
DNMT3A1, DNMT3A2, and DNMT3L coding regions have been
previously described [12,21]. The human DNMT3B4 cDNA was
created by a combination of restriction enzyme cloning and PCR
(primers available upon request) using pcDNA3/Myc-DNMT3B2
as a template, and was verified by sequencing. Expression vectors
for bacterial expression include a modified pGEX vector [12],
carrying an N-terminal glutathione S-transferase (GST) tag
followed by a 6X histidine tag prior to full-length or C-terminal
DNMT3 isoform cDNA; and a modified pMAL vector (NEB)
containing an N-terminal maltose-binding protein (MBP) tag
followed by a 6X histidine tag prior to full-length or C-terminal
DNMT3 isoform cDNA. Vectors were created by restriction
enzyme cloning and PCR, and verified by sequencing. C-terminal
DNMT3B2, DNMT3B3, and DNMT3B4 isoforms were missing the
coding region for their first 510 amino acids, and therefore
encoded for proteins that were 323, 260, and 214 amino acids
long, respectively. Note that C-terminal DNMT3B2 is equivalent
to C-terminal DNMT3B1 since DNMT3B2 and DNMT3B1 only
differ in their N-terminus. C-terminal DNMT3B isoforms were
codon-optimized for bacterial expression.
Episomal DNA
The pFC19 episome [7] was used as a DNA methylation target.
The episome contains the EBNA1/OriP replication system and
can be stably maintained in mammalian cells. The regions
analyzed for DNA methylation correspond to ,500 base pair
region of the pBR322 backbone, carrying 48 CpG sites [30] and a
1 kb region of the human SNRPN CpG island.
Protein Purification
Full-length human DNMT3A2 was purified as described
previously [12]. Human MBP-6X histidine-tagged full-length
DNMT3L (MBP-3L), C-terminal DNMT3B2 (MBP-3B2ct), C-
terminal DNMT3B3 (MBP-3B3ct), and C-terminal DNMT3B4
(MBP-3B4ct) proteins were purified from freshly transformed
Escherichia coli (E. coli) Rosetta (DE3) cells (Novagen) grown in LB
broth supplemented with ampicillin (100 mg/ml) and 0.2%
glucose. Protein expression was induced during exponential
growth with 0.5 mM isopropyl 1-thio-b-D-galactopyranoside and
the culture was incubated at 16uC overnight. Cells were harvested
and lysed in chilled amylose buffer (20 mM Tris-HCl pH 7.5,
150 mM NaCl, 0.1 mM EDTA, 0.1 mM dithiothreitol (DTT),
10 mg/ml RNase A, 0.5 mM phenylmethylsulfonyl fluoride, 0.1%
Triton X-100, and 1 complete, Mini, EDTA-free, protease
inhibitor cocktail tablet (Roche) using a microfluidizer. The lysate
was spun for one hour at 33,0006g to remove cellular debris and
the supernatant was subsequently loaded onto a 30 ml amylose
column. The column was washed with at least three column
volumes of amylose buffer and then bound protein eluted with
amylose buffer supplemented with 20 mM maltose. For MBP-
3B2ct, amylose elutions were dialyzed overnight in a low salt
buffer (20 mM Tris-HCl pH 7.5, 50 mM NaCl, 0.1 mM EDTA,
and 0.1 mM DTT) and then loaded onto a 1 ml Q column (GE
HealthCare) followed by a 1 ml SP column (GE Healthcare). The
flow-through of the Q and SP columns was then loaded onto a
5 ml heparin column (GE Healthcare), which was eluted with a
salt gradient up to 1.5 M NaCl after washing. MBP-3L was
purified as described for MPB-3B2ct except the SP column was
omitted. MBP-3B3ct was purified as described for MBP-3B2ct
except the heparin column was omitted. For MBP-3B4ct, amylose
elutions were loaded directly onto a heparin column after dialysis
in low salt buffer. After washing, bound protein was eluted using a
salt gradient as described. Heparin elutions were then dialyzed in
S200 buffer (20 mM Tris-HCl pH 7.5, 500 mM NaCl, 0.5 mM
EDTA, and 0.5 mM DTT) and run through an S200 size
exclusion column.
C-terminal and full-length co-complexes of MBP-6X histidine
tagged DNMT3B2 (MBP-3B2ct or MBP-3B2) with GST-6X
histidine tagged DNMT3B2 (GST-3B2ct or GST-3B2),
DNMT3B3 (GST-3B3ct or GST-3B3), or DNMT3B4 (GST-
3B4ct or GST-3B4) were obtained by overexpressing differentially
tagged DNMT3B isoforms in E. coli individually, and lysing
appropriate pairwise combinations of cells together. The clarified
lysates were then run through a 10 ml amylose column followed
by a 5 ml glutathione column. Growth, expression, lysis and
amylose column conditions were essentially as described above.
Elutions from the amylose column were dialyzed in GST binding
buffer (1 mM EDTA, 1 mM DTT, and 1X phosphate buffered
saline) overnight and loaded onto a 5 ml glutathione column,
which was washed with at least five column volumes of GST wash
buffer (50 mM Tris-HCl pH 8.5, 500 mM NaCl, 1 mM EDTA,
1mM DTT, and 0.01% Triton X-100) and eluted with GST wash
buffer supplemented with 4 mM reduced glutathione. The
resulting elutions contained co-complexes of GST and MBP-
tagged DNMT3B isoforms.
Inactive DNMT3B Variants Modulate DNA Methylation
PLOS ONE | www.plosone.org 2 July 2013 | Volume 8 | Issue 7 | e69486
Protein concentrations were determined by either a Bradford
assay and/or by their absorbance at 280 nm, using their molecular
weights and extinction coefficients. All purified proteins and
protein complexes were stored at280uC in storage buffer (20 mM
Tris-HCl pH 7.5, 150 mM NaCl, 0.1 mM EDTA, 0.1 mM DTT,
40% glycerol).
Cell Lines, Transfections and Immunocytochemistry
HEK293, HEK293c18, and NIH3T3 cell lines were grown
under standard conditions. Transient transfections for western
blots, immunoprecipitation experiments, or immunofluorescence
experiments were performed in either 6-well or 10 cm plates,
using either 0.5 mg or 2.5 mg of expression vectors, respectively,
unless otherwise specified. For immunoprecipitation experiments
and most western blots, cells were harvested 36 to 48 hours post
transfection by whole cell extract sonication lysis. The histone
enriched fraction was harvested by the acid extraction method.
Transfections for in vivo DNA methylation analysis were per-
formed in 6-well plates with 0.5 mg of expression vector and 0.5 mg
of episomal DNA, as described before [30]. All transfections were
performed at least in duplicate, using calcium phosphate,
Lipofectamine (Invitrogen), or Turbofect (Fermentas) methods.
Immunocytochemistry on transfected HEK293 cells was
performed on gelatinized glass coverslips using the common
formaldehyde/Triton X-100 fixation and permeabilization meth-
od. Primary antibodies (Mouse anti-FLAG: 1:150, Rabbit anti-
Myc: 1:100, Rabbit anti-H3K9me3:1:1000 (Abcam) were incu-
bated for one hour, washed three times and revealed using
fluorophore-conjugated secondary antibodies (1:200). After further
washing, coverslips were mounted on glass slides in a drop of
Vectashield Mounting Medium with DAPI (49, 6-diamidino-2-
phenylindole), and imaged using a fluorescence microscope.
Measurement of DNA Methylation Activity in vitro and
in vivo
In vitro DNA methylation patterns laid by full-length DNMT3B
isoform co-complexes were determined by bisulfite methylation
sequencing upon incubation of 1 mM purified recombinant MBP
and GST tagged co-complexes with 250 ng of pFC19 DNA
template in the presence of 100 mM S-Adenosyl-L- methionine
(SAM) in activity buffer (25 mM Tris-HCl pH 7.5, 50 mM KCl,
0.5 mM MgCl2, 100 mg/ml BSA, 1 mM DTT). The reactions
were incubated for 24 hours at 37uC (SAM was re-supplemented
fresh after 12 hours). After the 24 hour reaction, proteins were
removed by Proteinase K treatment followed by phenol chloro-
form extraction and ethanol precipitation. In vitro DNA methyl-
transferase activity was quantitated by measuring the transfer of
tritiated methyl groups from S-adenosyl-L-[methyl- H3] methio-
nine (H3-SAM) onto double stranded poly (dIdC) or pFC19 DNA
substrates as described previously [12]. In vivo DNA methylation of
the pFC19 target episome in HEK293c18 cells expressing various
DNMT3B isoforms was assessed by Southern blots and bisulfite
methylation sequencing as described previously [30].
Electromobility Shift Assays
DNA binding reactions were set up in activity buffer (25 mM
Tris-HCl pH 7.5, 50 mM KCl, 0.5 mM MgCl2, 100 mg/ml
bovine serum albumin, 1 mM DTT) supplemented with 10%
glycerol. Purified proteins were pre-incubated at varying concen-
trations for 10 minutes at 37uC before addition of 0.1 mM of
human DNA (a 420 base pair DNA fragment of the PWWP
domain of human DNMT3B described previously [10]). DNA
binding was allowed to reach equilibrium over 30 minutes at
37uC, at which point samples were loaded onto a 1% agarose gel
and run at 65 V for 1.5 hours. DNA binding was visualized by
ethidium bromide staining of the DNA fragment and analyzed via
ImageQuant software version 5.2. DNA binding reactions were
performed at least in duplicate.
Immunoprecipitation Experiments
Immunoprecipitation experiments were done as described
previously [21]. Briefly, pCDNA3/FLAG-DNMT3B1 was tran-
siently co-transfected with expression constructs for Myc-tagged
DNMT3B1, DNMT3B2, DNMT3B3, or DNMT3B4 isoforms.
After harvesting the cells, lysates were incubated with anti-FLAG
M2 affinity gel (Sigma) with rotation for three hours at 4uC. After
washing five times, proteins bound to the affinity gel were eluted
by competition with the FLAG peptide, separated by 8% SDS-
PAGE gels, and transferred to PVDF membranes. Thereafter,
western blots were performed with anti-FLAG (Sigma) and anti-
Myc (Roche) antibodies.
MBP Pull-downs
Purified MBP-tagged DNMT3B3ct (0.8 mM) and MBP-tagged
DNMT3L (0.8 mM) were each incubated with purified full-length
DNMT3A2 (0.8 mM) at 37uC for one hour in binding buffer
(25 mM Tris-HCl pH 7.5, 50 mM KCl, 0.5 mM MgCl2, 1 mM
DTT). 50 ml of amylose resin (NEB) was added to the protein co-
complexes and proteins were incubated an additional hour at 4uC
with gentle rocking. Co-complexes were washed three times in
binding buffer and then eluted with binding buffer supplemented
with 20 mM maltose. The resulting elutions were loaded on 8%
SDS-PAGE gels and visualized after electrophoresis by staining
with Coommassie brilliant blue.
Gel Filtration
100 mg of purified DNMT3B C-terminal proteins and C-
terminal DNMT3B isoform co-complexes were loaded onto a
Superose 6 HR 10/30 column controlled by an A¨KTAFPLC
system run by Unicorn version 4.00.16 software (GE Healthcare).
Superose 6 buffer (20 mM Tris-HCl pH 7.5, 150 mM NaCl,
0.1 mM EDTA, 0.1 mM DTT) was used for all experiments and
flow rate was kept constant at 0.3 ml/minute. Elution volumes
were determined using Unicorn software.
Results
DNMT3B3 and DNMT3B4 Interact with Active DNMT3
Proteins
We first tested whether DNMT3B3 and DNMT3B4 could bind
to active DNMT3B1 and/or DNMT3B2 enzymes (see Figure S1A
for a schematic of all DNMT3 variants used here). To determine
interaction patterns, we used a cell culture model and expressed
full-length FLAG-tagged DNMT3B1 with Myc-tagged
DNMT3B3 or DNMT3B4 in human HEK293 cells and
performed co-immunoprecipitation experiments. These assays
revealed that DNMT3B3 and DNMT3B4 physically interact with
DNMT3B1 (Figure 1A). To gain further evidence for this
interaction, we tested whether DNMT3B2 and DNMT3B3 or
DNMT3B4 isoforms co-localize in HEK293 cells. For this, we co-
expressed FLAG-tagged DNMT3B2 with Myc-tagged DNMT3B3
or DNMT3B4, and performed immunofluorescence experiments.
As expected, DNMT3B2 co-localized with DNMT3B3 and
DNMT3B4 in the nucleus of cells expressing both proteins
(Figure 1B), further suggesting that active and inactive DNMT3B
proteins physically interact in vivo.
Inactive DNMT3B Variants Modulate DNA Methylation
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We next tested whether DNMT3B3 and DNMT3B4 could bind
to active DNMT3B molecules in vitro. For this, we created
expression vectors for C-terminal or full-length DNMT3B1,
DNMT3B2, DNMT3B3, and DNMT3B4 isoforms, carrying
either an N-terminal MBP tag or an N-terminal GST tag.
DNMT3B isoforms were expressed recombinantly in E. coli, and
appropriate combinations of cells expressing differentially tagged
DNMT3B isoforms were lysed together and co-complexes purified
through sequential amylose and glutathione affinity columns.
Using this technique, we were able to show that DNMT3B2 (both
full-length and C-terminal versions) formed co-complexes with
itself as well as with DNMT3B3 and DNMT4B4 (Figure S1B).
Using MBP pull-down assays, we also showed that DNMT3B3
could interact with full-length DNMT3A2 protein at least as well
as DNMT3L under the same condition (data not shown). To
reveal the stoichiometry of each subunit within co-complexes, we
first used gel filtration chromatography: each C-terminal co-
complex eluted from a Superose 6 column at the void volume,
indicating that they form large molecular weight complexes
(Figure 1C). To determine the oligomerization profile of each
isoform individually, we purified MBP-tagged, C-terminal versions
of DNMT3B2, DNMT3B3, and DNMT3B4 (see Materials and
Methods for purification scheme and Figure S1C for protein
purity), and ran 100 mg of each purified protein on a Superose 6
column. As observed for co-complexes, each single isoform existed
as soluble high molecular weight aggregates eluting from Superose
6 at the void volume (data not shown). This was surprising given
that DNMT3L, which resembles DNMT3B3 and DNMT3B4 (see
Figure S1A), commonly forms monomer or dimers in solution
[11,12]. In order to gain insight into protein stoichiometry within
co-complexes, we used an anti-6X histidine antibody (which lights
up each fusion protein within co-complexes) and western blot to
quantify the intensities of each band. This showed that
DNMT3B2:DNMT3B2 and DNMT3B2:DNMT3B3 co-com-
plexes exist in roughly 1:1 stoichiometries while
DNMT3B2:DNMT3B4 co-complexes show a roughly 1:2 ratio
of DNMT3B2 to DNMT3B4 (Figure 1D). Thus, even though each
co-complex corresponds to a large high molecular weight
aggregate, it appears that each co-complex has a precise subunit
stoichiometry. Taken together, this data indicates that inactive
DNMT3B isoforms bind to active DNMT3 members and form
large molecular weight complexes of defined stoichiometries.
DNMT3B3 Associates with Active DNA Methylation
without Modifying DNA Methylation Patterns
In order to determine the effect of DNMT3B3 on DNA
methylation, we used a well-characterized episomal assay to
measure DNA methyltransferase activity in cell culture [7]. For
this, we transfected human HEK293c18 cells with a stably
replicating target episome, pFC19, and appropriate pair-wise
combinations of DNMT3 isoform expression vectors. After seven
to eight days, we recovered episomal DNA by Hirt harvest [31],
and assessed DNA methylation first by performing Southern blots
with probes to the episome after the DNA was digested with a
methylation-sensitive restriction enzyme. Southern blot analysis
using three different episomal probes (SNRPN, pFC19, or pBR),
confirmed that DNMT3B3 by itself is inactive (Figure 2A and
Figure S2A). By contrast, co-expression of DNMT3B3 with
DNMT3B2 or DNMT3A2, was consistent with active DNA
methylation but did not appear to introduce obvious changes in
the activity of DNMT3B2 or DNMT3A2 (Figure 2A and Figure
S2A).
We next sought to determine whether inclusion of DNMT3B3
in co-complexes could alter the DNA methylation patterns laid by
active DNMT3 molecules. To this end, we performed bisulfite
DNA methylation sequencing on the top and bottom strand of the
pBR region on the pFC19 episome after methylation in
HEK293c18 cells (Figure S2B and data not shown). The pBR
region, encompassing 500 base pairs and 48 distinct CpG sites,
was chosen because it has previously been shown to harbor clear
high and low sites for active DNMT3 enzymes [30]. In order to
allow comparison of the methylation patterns, we compared the
ranks of all CpG sites from highest to lowest based on their
frequency of DNA methylation. Consistent with previous data
[30], clear high and low efficiency sites were observed, but these
DNA methylation patterns remained mostly unchanged upon
DNMT3B3 co-expression (Figure 2B, Figure S2B, and data not
shown). Likewise, the DNA methylation patterns deposited in vitro
by purified full-length MBP-DNMT3B2:GST-DNMT3B2 and
MBP-DNMT3B2:GST-DNMT3B3 co-complexes on pFC19 epi-
somal DNA were similar to each other (Figure S3). Taken
together, our data confirms that DNMT3B3 is associated with
active DNA methylation [25] in a manner that does not alter
patterns of DNA methylation laid by active DNMT3 molecules.
DNMT3B3 Modulates the Frequency of de novo DNA
Methylation in Quantitative in vitro Assays
In order to measure potential subtle changes in DNA
methylation activity, we performed quantitative in vitro DNA
methylation activity assays using purified complexes. Consistent
with our in vivo data, purified DNMT3B3ct by itself was inactive
(data not shown). We titrated increasing amounts of MBP-
DNMT3B3ct into reactions containing a constant concentration
of full-length active DNMT3A2 protein. The proteins were
dialyzed in activity buffer overnight to avoid introducing any
buffer distortion and were pre-incubated with tritiated SAM for 15
minutes at 37uC before the reactions were initiated by addition of
the linear pFC19 DNA substrate. Activity was then measured after
45 minutes. In this assay, addition of DNMT3B3 led to a
progressive and reproducible increase in DNA methylation such
that DNMT3A2 activity was 3 to 4-fold higher when a 4-fold
molar excess of DNMT3B3 was included in the reaction
(Figure 2C). Note that the dose response curve did not show
evidence of a plateau which suggests that complex formation
between DNMT3A2 and DNMT3B3 was inefficient. Nonetheless,
this suggests that DNMT3B3 can modestly stimulate the activity of
active DNMT3 enzymes provided that co-complexes can be
formed.
During development, DNMT3B3 becomes highly expressed at
the onset of differentiation at a time when DNMT3L expression is
still high before it gradually decreases [24]. We therefore wished to
determine if DNMT3B3 could also affect the frequency of DNA
methylation in the presence of DNMT3L. For this, purified MBP-
DNMT3L, DNMT3A2 and MBP-DNMT3B3ct were pre-incu-
bated in activity buffer such that DNMT3A2 and DNMT3L were
kept at constant, equimolar, concentrations and DNMT3B3 was
added at increasing concentrations. Addition of DNMT3B3 led to
a progressive reduction in DNA methylation activity such that
activity in the presence of DNMT3B3 was up to 30% lower than
without it (Figure 2D). The maximal reduction was reached for a
1:1 molar stoichiometry of DNMT3B3 to DNMT3A2:DNMT3L
complexes, suggesting that specific co-complexes were formed.
Altogether, this suggests that DNMT3B3 exerts subtle, contrasting
effects on DNA methylation activity. By itself, it can modestly
stimulate de novo activity. When added together with DNMT3L, it
can counteract the stimulatory activity of DNMT3L and lead to
the formation of complexes with intermediate activity.
Inactive DNMT3B Variants Modulate DNA Methylation
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DNMT3B4 Inhibits DNMT3 Function
The impact of DNMT3B4 on DNA methylation activity was
first assessed using our in vivo episomal assay. Southern blots
consistently showed that co-expression of DNMT3B4 with
DNMT3B2, DNMT3A1, or DNMT3A2 resulted in a noticeable
reduction in DNA methylation when compared to expression of
each active enzyme alone (Figure 3A, Figure S4A, and data not
shown). This suggests that DNMT3B4 serves as a broad inhibitor
of DNMT3 function. Using bisulfite DNA methylation sequencing
on the same region analyzed above, we observed that co-
expression of DNMT3B4 with DNMT3B2 led to a significant
(p = 0.0082) 3-fold decrease in activity, consistent with DNMT3B4
acting as a dominant-negative inhibitor of de novo DNA methyl-
ation (Figure 3B). DNA methylation patterns, however, seemed for
the most part unchanged (Figure S4B).
We performed in vitro activity assays to assess DNA methylation
activity of purified DNMT3B2, DNMT3B4,
DNMT3B2:DNMT3B2 co-complexes, as well as
DNMT3B2:DNMT3B4 and DNMT3B4:DNMT3A co-complex-
es. Consistent with our in vivo data, we observed that DNMT3B4ct
by itself was inactive while DNMT3B2ct and
DNMT3B2:DNMT3B2 co-complexes (both full-length and C-
terminal) were active (data not shown). Purified
DNMT3B2:DNMT3B4 full-length and C-terminal co-complexes
were inactive, consistent with DNMT3B4 strongly inhibiting
DNMT3B function through complex formation (Figure 3C and
data not shown). Additionally, we show that pre-incubation of
MBP-DNMT3B4ct with active full-length DNMT3A2 also
hindered DNMT3A function in vitro, consistent with in vivo data
(Figure 3D). Taken together, our data suggests that DNMT3B4 is
a dominant-negative inhibitor of active DNMT3 function.
DNMT3B3 Weakens, While DNMT3B4 Strongly Inhibits,
DNA Binding by Active DNMT3B Molecules
To better understand the mechanism(s) by which DNMT3B3
and DNMT3B4 exert their effects on active DNMT3 molecules,
we investigated the DNA binding properties of DNMT3B2,
DNMT3B3, and DNMT3B4 either by themselves or as co-
complexes. For this, we performed electromobility shift assays
(EMSAs) with purified C-terminal DNMT3B2, DNMT3B3, and
DNMT3B4 isoforms; and C-terminal and full-length
DNMT3B2:DNMT3B2, DNMT3B2:DNMT3B3, and
DNMT3B2:DNMT3B4 co-complexes (Figure 4A, 4B and Figure
S5). By itself, C-terminal DNMT3B3 bound to a test DNA
fragment with similar affinity as C-terminal DNMT3B2; however,
C-terminal DNMT3B4 bound to DNA significantly less than C-
terminal DNMT3B2, as shown by the fact that its Kd for DNA
was 10-fold higher than the one measured for DNMT3B2
Figure 1. Inactive DNMT3B isoforms interact with active DNMT3 isoforms. (A) Combinations of Myc- and FLAG- tagged isoforms were
expressed in human HEK293 cells as indicated. Expression of Myc-tagged proteins was verified in the whole cell extract (WCE) by western blot (top).
FLAG immunoprecipitates (IP) were probed with FLAG antibody to verify the expression of FLAG-tagged DNMT3B1 (center). Myc-tagged proteins
associated with FLAG IP were revealed using an anti-Myc antibody (bottom). (B) Myc-tagged DNMT3B3 or Myc-tagged DNMT3B4 and FLAG-tagged
DNMT3B2 were expressed in HEK293 cells and their localization was analyzed by immunofluorescence as indicated. All DNMT3B2 and DNMT3B3 dual-
expressing cells showed co-localization of expression (100%; n= 49) and most DNMT3B2 and DNMT3B4 dual-expressing cells displayed co-
localization (96.2%; n = 52) Representative images of are shown. (C) Representative elution profiles from gel filtration chromatography are shown
revealing that DNMT3B co-complexes form high molecular weight aggregates indistinguishable in size. (D) Co-complexes between indicated
isoforms were purified through tandem affinity purification and the relative stoichiometry of each isoform in the complex was evaluated by western
blot using an anti-6X histidine antibody directed against the internal 6X histidine tag common to all isoforms. A representative blot is shown and
relative stoichiometric ratios are indicated below. Experiments were performed at least in triplicate.
doi:10.1371/journal.pone.0069486.g001
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(Figure 4C). In similar EMSA experiments performed using both
C-terminal and full-length DNMT3B co-complexes, we noticed
that DNMT3B2:DNMT3B2 co-complexes consistently bound
DNA with a slightly higher affinity than DNMT3B2:DNMT3B3
co-complexes (Figure 4B, 4D and Figure S5), suggesting that
DNMTB3 may weaken DNA binding by DNMT3B2. In all cases,
DNMT3B2:DNMT3B4 co-complexes bound to DNA much less
than DNMT3B2 homo-complexes (Figure 4B, 4D and Figure S5).
The poor ability of DNMT3B4 and DNMT3B4-containing
complexes to bind to DNA suggests that DNMT3B4 might exert
its inhibitory effects by sequestering active DNMT3 molecules
away from their DNA substrate. Binding in the presence of
DNMT3B3, by contrast, is only slightly reduced. In all cases, we
noted that the full-length DNMT3B co-complexes bound to DNA
with a higher affinity than C-terminal co-complexes, which
suggests that the DNMT3B N-terminus is involved in DNA
binding, as reported earlier [32].
DNMT3B Isoforms Drive Distinct DNA and H3K9me3
Staining
In order to gain further insights into how expression of
DNMT3B3 and DNMT3B4 might exert their functions in vivo,
we transiently overexpressed FLAG-tagged DNMT3B2,
DNMT3B3, and DNMT3B4 in HEK293 cells, and compared
their localization patterns using immunocytochemistry. Three
different DNMT3B localization patterns were observed: globular,
diffuse, and punctate (Figure 5). The majority of DNMT3B2 and
DNMT3B3-expressing cells displayed a globular expression
pattern, which was the least likely expression pattern for
DNMT3B4-overexpressing cells (Figure 5). DNMT3B4, in con-
trast, displayed a punctate distribution pattern, which was not
observed in any of the DNMT3B2 or DNMT3B3-expressing cells
(Figure 5). Similar localization patterns were also observed in
mouse NIH3T3 cells (Figure S6).
Interestingly, DNA organization, as observed by DAPI staining,
also varied depending on the specific DNMT3B isoform being
expressed (Figure 5). The majority of DNMT3B2 or DNMT3B3-
overexpressing cells displayed a condensed DNA staining pattern.
In most cases, this condensed staining pattern was associated with
Figure 2. DNMT3B3 modulates DNA methylation activity without affecting DNA methylation patterns. (A) HEK293c18 cells were
transfected with the pFC19 target episome and combinations of DNMT3 expression vectors, as indicated. DNA methylation was assessed by Southern
blot after digestion of episomal DNA with a methylation-sensitive restriction enzyme. Higher molecular weight bands are indicative of DNA
methylation. (B) Bisulfite sequencing was performed on a 500 base pair region of harvested episomal DNA. Co-expression of DNMT3B2 with
DNMT3B3 does not lead to a change in DNA methylation patterns as judged by the fact that the ordered ranks of the 48 methylation sites in the
region do not shift significantly. (C) Pre-incubation of DNMT3B3 with active DNMT3A2 leads to a stimulation of catalytic activity. The graph displays
the result of quantitative in vitro activity assays in which the incorporation of labeled methyl groups into DNA was measured at increasing ratios of
DNMT3B3ct to DNMT3A2. (D) DNMT3B3 hinders the stimulatory effect of DNMT3L. Pre-incubation of increasing concentrations of DNMT3B3ct to
constant amounts of DNMT3A2 and DNMT3L leads to a progressive decline in DNA methylation activity as measured in quantitative in vitro assays.
Results in panels C and D are from triplicate experiments and shown with average and standard deviations.
doi:10.1371/journal.pone.0069486.g002
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the DNMT3B2 or DNMT3B3 globular localization pattern,
suggesting that expression of DNMT3B2 or DNMT3B3 leads to
the formation of condensed, DAPI-bright, regions, an observation
consistent with the fact that DNMT3B associates with components
of the condensin complex [33]. DNMT3B4-expressing cells, on
the other hand, mostly displayed a diffuse DAPI staining pattern
no matter the type of DNMT3B4 expression pattern. The DNA
staining of DNMT3B4-expressing cells was similar to the DNA
staining observed in untransfected cells, suggesting that
DNMT3B4 expression does not alter DNA organization and/or
compaction. Expression of human DNMT3B4 in mouse NIH3T3
cells, similarly, resulted in DNA staining typical of untransfected
cells (Figure S6).
Given that DNMT3B is targeted to compacted, histone 3 lysine
9 tri-methylation (H3K9me3)-rich, pericentric heterochromatic
regions [34,35], we also analyzed whether the various DNMT3B
isoforms studied here caused any perturbation in the H3K9me3
staining pattern. In untransfected HEK293 cells, the H3K9me3
distribution was speckled in the majority of cases (Figure 5). In a
minority of cells, the H3K9me3 pattern was pronounced and
spotty, or alternatively, faint (Figure 5). Interestingly, expression of
DNMT3B2 and DNMT3B3 isoforms resulted in distinct alter-
ations of the H3K9me3 staining pattern. DNMT3B2 expression
shifted the H3K9me3 staining to a mostly faint pattern while
DNMT3B3 expression shifted the distribution to a mostly spotty
pattern. Most DNMT3B4-expressing cells displayed a speckled
H3K9me3 staining corresponding to the typical H3K9me3
staining of untransfected cells (Figure 5). A similar reduction in
H3K9me3 staining was observed when human DNMT3B2 was
expressed in mouse NIH3T3 cells (Figure S6). An increase in
spottiness upon DNMT3B3 expression could not be observed
upon DNMT3B3 expression in NIH3T3 cells (Figure S6);
however, this is likely due to the large chromocenters characteristic
of mouse NIH3T3 cells [36]. Like in HEK293 cells, DNMT3B4-
expressing NIH3T3 cells displayed characteristics resembling most
closely those of untransfected cells.
Since the majority of cells expressing DMT3B2 displayed a faint
H3K9me3 staining, we hypothesized that expression of
DNMT3B2 might be causing global H3K9me3 levels to be
reduced. In order to test this idea, we transfected HEK293 cells
Figure 3. DNMT3B4 inhibits DNMT3 activity. (A) Expression of DNMT3B4 inhibits DNA methylation in vivo as measured by Southern blots in
transfected HEK293c18 cells. See Figure 2A for further details. (B) In vivo methylation mediated by DNMT3B2 on its own (left) or by DNMT3B2 co-
expressed with DNMT3B4 (right) was assessed by bisulfite methylation sequencing. Co-expression of DNMT3B4 significantly reduces the overall
methylation efficiency over the entire region analyzed. Two independent transfections were analyzed. Bars: standard deviation. (C) Purified full-length
co-complexes that include DNMT3B4 are catalytically deficient as measured in in vitro time course experiments where the incorporation of labeled
methyl groups onto DNA is followed. (D) Pre-incubation of purified DNMT3B4 with DNMT3A2 leads to an inhibition of catalytic activity. The graph
depicts results from activity assays that followed the incorporation of labeled methyl groups onto DNA at increasing ratios of DNMT3B4ct to
DNMT3A2. Results in panels C and D are from duplicate experiments and shown with average and standard deviations.
doi:10.1371/journal.pone.0069486.g003
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Figure 4. DNMT3B3 weakens, while DNMT3B4 strongly inhibits, DNA binding by DNMT3B2. (A) Binding to a 420 base pair DNA fragment
was measured by EMSAs for increasing concentrations of C-terminal DNMT3B2, DNMT3B3 and DNMT3B4 proteins. Bound and unbound DNA species
are indicated. (B) DNA binding was also measured for C-terminal DNMT3B2:DNMT3B2, DNMT3B2:DNMT3B3, and DNMT3B2:DNMT3B4 co-complexes
at increasing protein concentrations. (C and D) Graphical representation of EMSAs from A and B, respectively, performed at least in triplicate. The
percent of protein bound to DNA was calculated by band quantification using ImageQuant. Points: mean, bars: standard error. Results were fit using
nonlinear regression, saturation-binding (one-site-specific binding with Hill slope). Kd values: 3B2ct = 0.22 mM, 3B3ct = 0.16 mM, 3B4ct = 2.42 mM,
3B2ct+3B2ct = 0.4 mM, 3B2ct+3B3ct = 1.5 mM, 3B2ct+3B4ct =N/A.
doi:10.1371/journal.pone.0069486.g004
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with increasing amounts of DNMT3B2-expressing vector and
used quantitative western blotting to measure H3K9me3 levels
with a modification-specific antibody. Gradual overexpression of
DNMT3B2 as a function of vector amounts was verified via
western blot with an anti-FLAG antibody (data not shown). Equal
amounts of histone-extracted samples were then loaded on an
SDS-PAGE gel and processed for western blot with an anti-
H3K9me3 antibody. No consistent decrease in global H3K9me3
levels upon expression of DNMT3B2 could be demonstrated
despite multiple attempts (data not shown), suggesting that
DNMT3B2 expression might be causing a re-distribution of
H3K9me3 rather than a global reduction. Further experiments
are needed to confirm this hypothesis.
Discussion
Using DNMT3L as a paradigm for the regulation of active
DNMT3 enzymes by inactive DNMT3 variants, we set out to
determine if inactive DNMT3B splice variants could bind to and
modulate the activity of catalytically competent DNMT3 mem-
bers. Our results reveal that the DNMT3B3 and DNMT3B4
variants follow this paradigm, albeit result in distinct consequences
on activity and involve distinct types of interactions.
Like previous studies with DNMT3L, we show that inactive
DNMT3B3 and DNMT3B4 proteins bind to active DNMT3A
and/or DNMT3B molecules in vivo and in vitro, although the types
of complexes formed appear distinct from those formed by
DNMT3L. As observed for DNMT3A [1,12,37], active
DNMT3B isoforms both self-interact and interact with each
other, which is consistent with several prior studies [10,32,38].
Unlike DNMT3L, however, DNMT3B3 and DNMT3B4 formed
large soluble homo-complexes, an observation reported indepen-
dently for DNMT3B3 [32]. This is surprising, particularly in the
case of DNMT3B4, given the resemblance of the C-terminus of
these isoforms to DNMT3L (Figure S1A), a protein that exists
mostly as monomers or dimers in solution [11,12]. This suggests
that there are uncharacterized DNMT3B3 and DNMT3B4 self-
interaction regions within the C-terminus of these isoforms. In
addition, the reorganization of large active DNMT3A or 3B
complexes into smaller heterodimers observed upon DNMT3L
interaction [11,12] does not seem to occur upon DNMT3B3 or
DNMT3B4 interaction. Gel filtration chromatography instead
revealed that purified DNMT3B2:DNMT3B2,
DNMT3B2:DNMT3B3, and DNMT3B2:DNMT3B4 co-com-
plexes still exist as large soluble aggregates. Despite this, western
blots suggested that these co-complexes are of defined stoichiom-
etries. DNMT3B2 interacts with DNMT3B3 in a 1:1 molar ratio,
while DNMT3B2 and DNMT3B4 appear to interact with a 1:2
ratio. It will be interesting to determine how subtle differences in
the domain structures of DNMT3B3 and DNMT3B4 (see Figure
S1A) account for the differences in stoichiometric ratios once
isoform-specific structural information becomes available. The
functional relevance of the DNMT3B2:DNMT3B4 stoichiometric
ratio is unclear, although it might ensure that overexpression of
DNMT3B4 is necessary to reveal the effect of DNMT3B4. It
should be noted that the ability of DNMT3B3 or DNMT3B4 to
interact with active DNMT3A or DNMT3B isoforms is much
reduced compared to DNMT3L. Unlike DNMT3L, simple pre-
incubation of various isoforms in activity buffer was mostly
insufficient to allow formation of mixed complexes (data not
shown). Instead, mixed co-complexes could be most readily
recovered if the isoforms were either co-expressed or co-purified
together directly from cells. Taken together, our data demonstrates
that inactive DNMT3B variants can participate in mixed co-
complexes with active DNMT3 enzymes, but that their mode of
interactions are distinct from those described previously for
DNMT3L.
While DNMT3L, DNMT3B3, and DNMT3B4 all bind to
active DNMT3 members, they have drastically different effects on
DNA methylation efficiency. The DNMT3L stimulatory factor
can enhance de novo DNA methylation up to 20-fold in
reconstituted biochemical assays [10,12]. In the case of
DNMT3B4, interaction results in a 3-fold reduction of activity,
consistent with several reports linking DNMT3B4 expression to
DNA hypomethylation [20,29]. The DNMT3B3 splice variant, by
contrast, stimulated de novo DNA methylation, but did so modestly,
leading to a 3 to 4-fold increase of activity (Figure 2C). This
observation is consistent with evidence that the expression of
DNMT3B3 is associated with active DNA methylation [25] and
with a previous report suggesting that DNMT3B3 may act as a
weak stimulator of DNA methylation [32]. Unlike DNMT3L,
which exerts its maximal stimulatory effect at a 1:1 molar ratio, we
observed that excess concentrations of DNMT3B3 over
DNMT3A2 were required for stimulation. This probably reflects
the fact that DNMT3B3:DNMT3A2 co-complexes form only
inefficiently under our conditions. If correct, this suggests that the
Figure 5. DNMT3B isoforms drive unique and distinct localization, DNA staining, and H3K9me3 patterns in human cells. FLAG-
tagged DNMT3B2, DNMT3B3, and DNMT3B4 were transiently transfected into human HEK293 cells. 24 to 36 hours later, cells were fixed and stained
with anti-FLAG (Sigma) and anti-H3K9me3 (Abcam) antibodies. Transfections were repeated at least in triplicate and cells were photographed with a
fluorescence microscope. Representative DNMT3B (Globular, Diffuse, or Speckled: red), DNA (Condensed or Diffuse: blue), and H3K9me3 (Speckled,
Spotty, or Faint: green) staining are depicted. Percentages of each type of staining versus DNMT3B isoform expressed are indicated below each
image. The total number of independent cells analyzed: DNMT3B2, n = 237; DNMT3B3, n = 203; DNMT3B4, n = 215; none, n = 356.
doi:10.1371/journal.pone.0069486.g005
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true ability of DNMT3B3 to stimulate de novo methylation may
have been under-estimated in our assays. Interestingly, incubation
of DNMT3B3 together with DNMT3A2 in the presence of
equimolar DNMT3L concentrations led to a progressive and
reproducible reduction of DNA methylation efficiency such that
activity was 30% reduced by DNMT3B3. Unlike what we
observed for bi-molecular complexes, the maximal effect of
DNMT3B3 was observed for a 1:1 stoichiometry of DNMT3B3
to DNMT3A2 and DNMT3L (Figure 2D). This striking difference
in dose response between bi- and tri-molecular complexes suggests
that DNMT3L may facilitate the interaction between DNMT3B3
and DNMT3A2. Whether tri-molecular
DNMT3B3:DNMT3A2:DNMT3L or bi-molecular
DNMT3B3:DNMT3A2 complexes ultimately result from the
interaction of these three proteins remains to be determined. It
should be noted that a recent study [32] reported that DNMT3B3
caused a ,20% increase in DNA methylation in the context of tri-
molecular DNMT3B3:DNMT3A2:DNMT3L complexes, con-
trasting with the ,30% decrease reported here. The difference
between these studies could be due to differences in buffer
conditions (high EDTA in [32] compared to a more physiological
Mg-containing buffer here) or to the fact that our studies were
limited to the C-terminal domain of DNMT3B3. Altogether, our
study suggests that DNMT3B3 is capable of counteracting the
stimulatory function of DNMT3L. In the absence of DNMT3L,
however, DNMT3B3 appears to stimulate the activity of DNMT3
enzymes although this property may be limited by the difficulty of
forming bi-molecular complexes. Such contrasting behavior may
enable the transition from a maximal de novo methylation activity
fueled by DNMT3L in early development to an intermediate level
once DNMT3B3 becomes expressed. Once DNMT3L expression
is down-regulated, DNMT3B3 expression, which is common in
most somatic cells, could maintain de novo DNA methylation
slightly above a baseline level in the absence of DNMT3L. Such a
hypothesis is consistent with the dynamics of expression of the
various isoforms involved [24], and the dynamics of DNA
methylation activity through development (Figure S7). Altogether,
our results show that inactive DNMT3 variants including
DNMT3L and DNMT3B splice variants, can have a profound
impact on de novo DNA methylation, modulating the efficiency of
active DNMT3A or DNMT3B enzymes over at least a 60-fold
range (Figure 6).
While all inactive DNMT3 variants studied so far appear to
exert their effects on de novo DNA methylation through the
formation of co-complexes with active DNMT3 molecules, the
consequences of these interactions are distinct. DNMT3L operates
by promoting the rearrangement of large DNMT3A2 complexes
into defined hetero-dimeric sub-complexes with increased catalytic
potential, higher affinity for SAM, and higher processivity
[11,12,13]. DNMT3L, however, does not seem to affect DNA
binding by DNMT3A [12]. DNMT3B4, by contrast, appears to
cause a sharp reduction in DNA binding affinity in its co-
complexes. We suggest that this reduction is the cause of the broad
inhibitory effects of this isoform on DNA methylation. This is in
contrast to the hypothesis that DNMT3B4 might function by
outcompeting active DNMT3B isoforms for targeting to DNA
regions, resulting in DNA hypomethylation [20]. Indeed this
model is not compatible with our evidence that DNMT3B4 binds
to DNA only weakly, suggesting instead that DNMT3B4 functions
by sequestering active DNMT3 molecules away from DNA.
Unlike DNMT3B4, the DNMT3B3 isoform is still capable of
strong DNA binding albeit DNMT3B3:DNMT3B2 co-complexes
show slightly reduced binding, in agreement with an independent
report [32]. We suggest that the slightly weakened DNA binding
might result in faster turnover of co-complexes, thereby explaining
the ability of DNMT3B3 to modestly stimulate DNA methylation.
This interpretation is consistent with analyses indicating that the
rate-limiting step for catalysis by the model HhaI cytosine
methyltransferase corresponds to the final dissociation step from
the reaction’s products [39]. Furthermore, we note that a
DNMT3B1 ICF syndrome mutation, R823G, was recently
reported to show a profound DNA methylation defect caused by
DNA dissociation defect [10].
In addition to affecting intrinsic catalytic properties, it is possible
that DNMT3B variants also modulate de novo DNA methylation
indirectly through effects on chromatin condensation and modi-
Figure 6. Inactive DNMT3 variants modulate DNA methylation activity. DNMT3L, the prototypic inactive DNMT3 variant stimulates de novo
methylation activity up to 20-fold from a baseline level up to maximal methylation levels [12]. Stimulation is graphically depicted by a vertical arrow.
DNMT3B3, by contrast, can both hinder the stimulatory effect of DNMT3L (shown by a downward pointing arrow) and stimulate the activity of active
DNMT3s from their baseline levels (shown by an upward pointing arrow). DNMT3B4, by contrast, inhibits DNA methylation 3-fold lower than baseline
level. Altogether, inactive DNMT3 variants can modulate de novo methylation activity over a 60-fold range.
doi:10.1371/journal.pone.0069486.g006
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fication. Immunocytochemistry experiments suggest that expres-
sion of DNMT3B2 or DNMT3B3, but not DNMT3B4, drive
chromatin condensation. This is consistent with the fact that
overexpression of Dnmt3a in fly causes irregular chromosome
condensation, DNA hypermethylation, and elevated levels of both
di-and tri-methyl H3K9 in pericentromeric regions [40]. Likewise,
it is consistent with the fact that DNMT3B has been shown to
interact with components of the condensin complex [33].
Interestingly, our immunofluorescence experiments also revealed
that expression of DNMT3B2, DNMT3B3, and DNMT3B4 had
different effects on H3K9me3 staining. While DNMT3B4-
expressing and untransfected cells mainly displayed a speckled
H3K9me3 staining pattern, DNMT3B2-expressing cells mainly
showed a faint H3K9me3 staining. By contrast, DNMT3B3-
expressing cells mainly displayed localized ‘‘spotty’’ increases in
H3K9me3 staining. The significance of these results remains to be
clarified, but fall into an accumulating body of data showing that
H3K9me3, DNA methylation, and DNMT3B are tightly linked
[41,42,43]. Since DNMT3B3 expression appears to favor DNA
condensation and the formation of H3K9me3-dense regions,
DNMT3B3 might favor the redirection of de novo DNA
methylation towards pericentric H3K9me3-rich heterochromatic
regions. DNMT3B4, on the other hand, does not appear to be
associated with H3K9me3 and its diffuse localization pattern is
consistent with poor binding to DNA. DNMT3B4 expression
could thus further drive a hypomethylation phenotype by severing
the connection between active DNMT3A and DNMT3B from
their normal targets both at the DNA and chromatin levels. This
notion is consistent with the observation of DNA hypomethylation
at pericentromeric satellite sequences upon overexpression of
DNMT3B4 in human hepatocarcinoma [20].
In summary, our work contributes new insights into the
regulation of de novo DNA methylation by inactive DNMT3B
isoforms in human cells. Most importantly, our work provides
clear evidence that inactive DNMT3B3 and DNMT3B4 splice
variants, like DNMT3L, interact with active DNMT3 family
members and modulate DNMT3 function upon complex forma-
tion, providing a general mechanism for the regulation of the
activity of DNMT3 family members. Likewise, our work illustrates
how overexpression of inactive DNMT3B variants may lead to the
generation of aberrant DNA methylation patterns in diseases such
as cancer. Finally, our work indicates that while most studies have
naturally focused on understanding the function of active
DNMT3A or DNMT3B molecules, the potential regulatory role
of inactive DNMT3 variants should not be ignored, especially in
light of the fact that over thirty, mostly inactive, isoforms are
expressed from the DNMT3B locus alone.
Supporting Information
Figure S1 DNMT3 variants and protein purity. (A)
Schematic of the structure of DNMT3 variants with major protein
domains indicated. (B and C) Aliquots (,1 mg) of purified
DNMT3 co-complexes and proteins run on 8% SDS-polyacryl-
amide gels stained with Coomassie Brilliant Blue.
(TIF)
Figure S2 DNMT3B3 modulates DNA methylation ac-
tivity without affecting DNA methylation patterns. (A)
HEK293c18 cells were transfected with the pFC19 target episome
and combinations of DNMT3 expression vectors, as indicated.
DNA methylation was assessed by Southern blot with the pBR
probe after digestion of episomal DNA with a methylation-
sensitive restriction enzyme. Higher molecular weight bands are
indicative of DNA methylation. (B) In vivo methylation mediated
by DNMT3B2 on its own (top) or by DNMT3B2 in the presence
of DNMT3B3 (bottom) was assessed by bisulfite methylation
sequencing (the pBR 500 base pair region containing 48 CpG sites
was chosen). Two independent transfections were analyzed and
combined. Closed symbols indicate methylation, open symbols
indicate no methylation. The patterns of methylation do not
appear to have shifted as high methylation sites and low
methylation sites largely remain the same.
(TIF)
Figure S3 DNMT3B3 does not alter DNA methylation
patterns in vitro. Activity assays were performed with purified
full-length DNMT3B2:DNMT3B2 and DNMT3B2:DNMT3B3
co-complexes on pFC19 DNA overnight. Bisulfite sequencing was
performed on a 500 base pair region of the episome revealing that
DNMT3B3 does not lead to a significant change in DNA
methylation patterns as judged by the lack of significant shift in the
rankings of the 48 methylation sites analyzed here.
(TIF)
Figure S4 DNMT3B4 inhibits DNA methylation activity
of DNMT3B2 but does not alter DNA methylation
patterns in vivo. (A) HEK293c18 cells were transfected with
the pFC19 target episome and combinations of DNMT3
expression vectors, as indicated. DNA methylation was assessed
by Southern blot with the pBR probe after digestion of episomal
DNA with a methylation-sensitive restriction enzyme. Higher
molecular weight bands are indicative of DNA methylation. (B)
Patterns of DNA methylation mediated by DNMT3B2 (top) or
DNMT3B2 in the presence of DNMT3B4 (bottom) were assessed
by bisulfite methylation sequencing. Two independent transfec-
tions were analyzed and combined. Closed symbols indicate
methylation, open symbols indicate no methylation. While an
overall reduction of DNA methylation is clearly observed, the
patterns do not appear to have shifted.
(TIF)
Figure S5 DNMT3B3 and DNMT3B4 hinder DNA bind-
ing by DNMT3B2. Representative EMSA gels for full-length
DNMT3B2:DNMT3B2, DNMT3B2:DNMT3B3, and
DNMT3B2:DNMT3B4 complexes at increasing protein concen-
trations are shown. A 420 base pair DNA fragment (0.1 mM) was
used as a target.
(TIF)
Figure S6 DNMT3B isoforms drive unique and distinct
localization, DNA staining, and H3K9me3 patterns in
mouse cells. Human FLAG-tagged DNMT3B2, DNMT3B3, or
DNMT3B4 were transiently transfected into mouse NIH3T3 cells
and immunofluorescence experiments performed with anti-FLAG
and anti-H3K9me3 antibodies. See Figure 5 for further details.
The total number of independent cells analyzed: DNMT3B2,
n = 122; DNMT3B3, n= 66; DNMT3B4, n= 58; none, n= 486.
(TIF)
Figure S7 DNMT3 variant expression and de novo DNA
methylation during mammalian development.
DNMT3A2, DNMT3L, and DNMT3B1 are highly expressed
during early development, taking part in establishing global DNA
methylation patterns. Upon differentiation, DNMT3B3 becomes
highly expressed while DNMT3B1 expression is abruptly shut
down. During development, expression of DNMT3A and
DNMT3B gradually shifts to DNMT3A1 and DNMT3B2,
respectively, while DNMT3L expression is gradually reduced.
DNMT3A1, DNMT3B2, and DNMT3B3 take part in completing
global DNA methylation patterns. DNMT3B3 is the major splice
variant in somatic cells [23] and likely plays a role in directing
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DNA methylation towards condensed H3K9me3-rich pericentric
repeats. Adult tissues generally express low levels of DNMT3
variants and display tissue specific expression of DNMT3B4. In
Hepatocellular Carcinomas (HCC) DNMT3B4 becomes highly
expressed, and such overexpression is associated with global loss of
DNA methylation at pericentric repeats [21].
(TIF)
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